Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Vet Med Assoc ; 262(7): 904-908, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38503044

ABSTRACT

OBJECTIVE: To assess the level of anxiolysis achieved by alprazolam and gabapentin in hospitalized cats prior to elective ovariohysterectomy and to evaluate the sedative effects of these agents. ANIMALS: 60 client-owned female cats classified as American Society of Anesthesiologists physical status 1, admitted for elective ovariohysterectomy at a veterinary teaching hospital. METHODS: The cats were prospectively and randomly allocated into 3 groups. Ninety minutes before evaluation, group G received gabapentin (100 mg/cat), group A received alprazolam (0.125 mg/cat), and group P received no medication (placebo). Stress, enclosure activity, and sedation scores were blindly evaluated. RESULTS: Stress scores were similar in cats treated with gabapentin and alprazolam and gabapentin-treated cats had significantly lower stress score than those of the placebo group. Enclosure activity levels did not differ among the groups. Additionally, gabapentin and alprazolam resulted in similar sedation levels 90 minutes after treatment, which differed significantly compared to placebo. CLINICAL RELEVANCE: The results of this study suggest that gabapentin provides similar anxiolysis in cats to that of alprazolam when evaluated 90 minutes after administration. Although no difference was noted in sedation levels between gabapentin and alprazolam, both induced deeper sedation than placebo.


Subject(s)
Alprazolam , Anti-Anxiety Agents , Gabapentin , Animals , Gabapentin/administration & dosage , Gabapentin/pharmacology , Alprazolam/administration & dosage , Alprazolam/pharmacology , Cats , Female , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/pharmacology , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/pharmacology , Ovariectomy/veterinary , Hysterectomy/veterinary , Administration, Oral , gamma-Aminobutyric Acid/administration & dosage
2.
Front Vet Sci ; 11: 1338894, 2024.
Article in English | MEDLINE | ID: mdl-38523714

ABSTRACT

Introduction: Resistant epileptic episodes, such as refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE), are neurological emergencies that require immediate medical treatment. Although inhalational anesthetics, such as isoflurane (ISO), have been proposed as a means of seizure control in dogs, there is currently a lack of both experimental and clinical studies on this subject. Study design: This is a retrospective clinical study. Methods: Records of dogs that received ISO for the management of RSE and SRSE during their intensive care unit (ICU) hospitalization at the Companion Animal Clinic of the Aristotle University of Thessaloniki were included in the present study. The study period spanned from February 2013 to March 2023. Dogs were identified as responders (R) when RSE/SRSE ceased after ISO administration, and the dogs were successfully discharged from the ICU after ISO discontinuation. Dogs were identified as non-responders (NR) when RSE/SRSE ceased after ISO administration, but RSE/SRSE reoccurred after ISO discontinuation. Additional data about the number and time of ISO cycles, the time of ICU hospitalization, the side effects of ISO administration, and an additional administration of antiepileptic drugs (AEDs) and anesthetic drugs were also recorded. Results: A total of 20 dogs with 26 recorded RSE/SRSE episodes and 26 anesthetic cycles with ISO were included in the present study. The clinical termination of seizure activity was achieved 100% (26/26) in all episodes. In 73.1% (19/26) of the episodes, ISO administration resulted in successful RSE/SRSE treatment. Poor outcome was recorded in 26.9% (7/26) of the episodes because RSE/SRSE reoccurred after ISO discontinuation, and the dogs were euthanatized or died due to cardiac arrest. Inspiratory ISO ranged between 0.5 and 4.0%. The median time of the anesthetic cycles with ISO was 12.67 h (4.00-62.00). The median duration of the ICU hospitalization was 48.00 h (24.00-120.00). At least one ISO-related side effect was recorded in 23 out of 26 (88.5%) episodes. Conclusion: To the authors' knowledge, this is the first clinical study that addresses the administration of ISO for RSE/SRSE treatment in dogs. The use of ISO may be beneficial in terminating RSE/SRSE; however, further prospective studies are necessary to confirm this observation.

3.
J Am Vet Med Assoc ; 259(1): 56-61, 2021 Jul 01.
Article in English | MEDLINE | ID: mdl-34125612

ABSTRACT

OBJECTIVE: To determine whether IV propofol administration at a dose of 2 mg/kg (0.9 mg/lb) could induce food consumption by anorectic female dogs following elective ovariohysterectomy. ANIMALS: 51 healthy female dogs that failed to eat voluntarily when food was offered 6 hours after ovariohysterectomy. PROCEDURES: In a randomized, blinded, controlled clinical trial, dogs received propofol (2 mg/kg; n = 31) or an equivalent volume of saline (0.9% NaCl) solution (20) IV 6 hours after ovariohysterectomy. Afterward, food was offered to the dogs and food consumption was reassessed. Pain, sedation, and stress were scored before and immediately after treatment. RESULTS: 27 of the 31 (87%) dogs in the propofol group consumed food immediately after administration of the assigned treatment, whereas only 1 of 20 (5%) dogs in the placebo group did. No difference in pain, sedation, or stress scores was identified between the 2 groups. Sedation scores for dogs in the propofol group increased immediately after propofol administration. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that food consumption following elective surgical procedures can be effectively induced in anorectic female dogs by IV administration of propofol at a dose of 2 mg/kg.


Subject(s)
Appetite Depressants , Dog Diseases , Propofol , Animals , Dogs , Female , Hysterectomy/adverse effects , Hysterectomy/veterinary , Ovariectomy/veterinary , Pain, Postoperative/veterinary , Propofol/adverse effects
4.
Top Companion Anim Med ; 44: 100535, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33933700

ABSTRACT

Tetanus in dogs is a relatively uncommon neurological disease caused by the sporogenic bacillus Clostridium tetani. This disease is associated with prolonged hospitalization and mortality rates from 8%-50%. A 2-year-old, neutered male King Charles Spaniel and an approximately 8-months-old female Mongrel dog presented to Companion Animal Clinic with symptoms of muscle rigidity and generalized stiffness. A tentative diagnosis of generalized tetanus was made in both dogs. Treatment consisted of IV fluids, antibiotics (metronidazole), human tetanus antitoxin, analgesics and supportive care. Muscle relaxation was provided by midazolam. Acetylpromazine meleate was added to the treatment of the second dog to better control excitability. Each dog received magnesium therapy on the 10th and 3rd days, respectively; which was provided per os to the first dog and constant rate infusion (4 mg/kg/h) to the second dog. The addition of magnesium helped to increase muscle relaxation and increased the time interval between acetylpromazine administration. On the tenth day, magnesium sulfate was discontinued from the second dog and magnesium aspartate (12 mg/kg), twice a day, per os was administered in both animals. Further muscle relaxation was noted in both dogs with a substantial reduction of tetanus symptoms. Both dogs were discharged from Intensive Care Unit on the 14th and 13th day respectively with sole treatment of magnesium aspartate (12 mg/kg) orally, twice a day. Magnesium aspartate was continued for 14 days and 12 days respectively. Both dogs had progressive reduction of muscle rigidity and the first dog recovered completely. The second dog presented again with muscle rigidity and increased spinal reflexes after the discontinuation of magnesium aspartate, thus therapy with magnesium aspartate was started again and symptoms subsided after the second oral dose of magnesium. Therapy was continued for two more weeks during which muscle rigidity subsided and then was stopped. At that time, tetanus symptoms did not relapse and the dog was considered fully recovered. According to the findings of this case series, magnesium therapy may provide further muscle relaxation during the standard therapeutic protocol of tetanus in dogs. In addition, long term symptoms of the disease were adequately managed with the administration of magnesium aspartate, orally.


Subject(s)
Dog Diseases , Tetanus , Animals , Clostridium tetani , Dog Diseases/drug therapy , Dogs , Female , Magnesium/therapeutic use , Magnesium Sulfate , Male , Metronidazole , Tetanus/drug therapy , Tetanus/veterinary
SELECTION OF CITATIONS
SEARCH DETAIL
...